Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Melatonin/tetrahydrocannabinol - India Globalization Capital

Next Previous
Drug Profile

Melatonin/tetrahydrocannabinol - India Globalization Capital

Alternative Names: IGC-AD1

Latest Information Update: 20 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of South Florida
  • Developer India Globalization Capital
  • Class Anti-inflammatories; Antidementias; Cannabinoids; Chemoprotectants; Hormones; Non-opioid analgesics; Radioprotectives; Sleep disorder therapies; Small molecules; Tryptamines
  • Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 modulators; G protein-coupled receptor modulators; Inflammasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Dementia

Most Recent Events

  • 17 Aug 2026 India Globalization Capital completes enrolment in the phase IIb CALMA trial in Dementia (In the elderly, In adults) in USA, Canada, Colombia, Puerto Rico (PO, Liquid) (NCT05543681)
  • 26 Nov 2024 Efficacy and adverse events data from a phase II trial in Dementia released by IGC Pharma
  • 26 Nov 2024 Pharmacodynamics data from a preclinical trial in Dementia released by IGC Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top